Beta Drugs (NSE:BETA) EPS (Basic): ₹17.33 (TTM As of Mar. 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
82 GF Score
Price ₹2,096.60
GF Value ₹1,959.98
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs EPS (Basic)?

Beta Drugs NSE:BETA -3.13% 82 EPS (Basic) is ₹17.33 as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 82/100 and a GF Value™ of ₹1,959.98 (Fairly Valued). The stock has 6 warning signs investors should review.

Beta Drugs's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹8.93. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹17.33.

Beta Drugs's EPS (Diluted) for the three months ended in Mar. 2026 was ₹8.93. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹17.33.

Beta Drugs's EPS without NRI for the three months ended in Mar. 2026 was ₹8.93. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 17.33.

During the past 12 months, Beta Drugs's average EPS without NRIGrowth Rate was -9.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 10.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 26.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 37.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Beta Drugs's highest 3-Year average EPS without NRI Growth Rate was 480.80% per year. The lowest was 10.40% per year. And the median was 44.00% per year.

Beta Drugs  (NSE:BETA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Beta Drugs EPS (Basic) Related Terms

Beta Drugs EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Beta Drugs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs EPS (Basic) Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.59 30.43 37.90 42.02 40.92

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.31 9.40 0.00 8.40 8.93
NSE:BETA
82GF Score
Beta Drugs Ltd NSE:BETA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Beta Drugs's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(414.827-0)/10.138
=40.92

Beta Drugs's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(90.489-0)/10.133
=8.93

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹17.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹17.33 mean?
Beta Drugs (NSE:BETA) has a EPS (Basic) of ₹17.33 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' EPS (Basic) too high?
Beta Drugs' current EPS (Basic) is ₹17.33. Overall, Beta Drugs has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' EPS (Basic) compare to ZTS?
Beta Drugs' EPS (Basic) of ₹17.33 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Beta Drugs and its competitors. Beta Drugs's current EPS (Basic) is ₹17.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,959.98, compared to a current price of ₹2,096.60 — trading 7% above its estimated fair value. The current EPS (Basic) is ₹17.33. Beta Drugs' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current EPS (Basic) is ₹17.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,096.60 is trading 7% above its estimated GF Value™ of ₹1,959.98. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • EPS (Basic): ₹17.33
  • GF Value™: ₹1,959.98 vs. price of ₹2,096.60 (7% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score

Get the complete analysis for NSE:BETA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,096.60
Price
₹1,959.98
GF Value